Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (738)	12/23/1999 8:09:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Neuropathic pain clinical results will be out mid to late January. NTII had led me to believe that the results of the Phase II clinical trial of memantine for neuropathic pain would be announced before the end of December. However, I found out when I called the company that there are no results as of yet and there won't be before mid January at the earliest. This does not reflect a problem with the results as the blind has not yet been broken. So, NTII doesn't know internally what the results are like yet. The problem is simply the time it takes to analyze the results from a large trial with a small staff. So, NTII longs, kick back, enjoy the holidays, and be prepared for a very significant Q1. Best regards